<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="patients planned to be treated with traditional agents, such as" exact="cyclophosphamide" post="and glucocorticoids, particularly in the setting of resolved HBV"/>
 <result pre="(HR) has been reported at 5.1.25 Peak doses of &amp;gt;40 mg" exact="prednisolone" post="equivalents were associated with an adjusted HR for HBVr"/>
 <result pre="1 year and 5.5% at 10 years. GC peak daily dose &amp;gt;20 mg" exact="prednisolone" post="equivalents and treatment duration for &amp;gt;4 weeks were independent risk"/>
 <result pre="and expert advice suggests that daily doses of GCs &amp;gt;20 mg" exact="prednisolone" post="equivalents for treatment durations &amp;gt;4 weeks should be considered as"/>
 <result pre="of MTX).35 With regards to other non-biologic agents such as" exact="leflunomide" post="(LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ), and azathioprine (AZA), cases"/>
 <result pre="With regards to other non-biologic agents such as leflunomide (LEF)," exact="sulfasalazine" post="(SSZ), hydroxychloroquine (HCQ), and azathioprine (AZA), cases of HBVr"/>
 <result pre="to other non-biologic agents such as leflunomide (LEF), sulfasalazine (SSZ)," exact="hydroxychloroquine" post="(HCQ), and azathioprine (AZA), cases of HBVr are extremely"/>
 <result pre="agents such as leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ), and" exact="azathioprine" post="(AZA), cases of HBVr are extremely rare, and these"/>
 <result pre="rheumatology field are limited, Li and colleagues compared a standard" exact="prednisone" post="regimen (1 mg/kg daily) versus MMF (500–1000 mg twice daily) and"/>
 <result pre="regimen (1 mg/kg daily) versus MMF (500–1000 mg twice daily) and lower" exact="prednisone" post="dose (0.5 mg/kg daily) in HBsAg-positive patients with idiopathic nephrotic"/>
 <result pre="in 64% (14/22) and 37% (7/19) of patients on standard" exact="prednisone" post="monotherapy and MMF/lower prednisone combination, respectively (p = 0.047), highlighting the"/>
 <result pre="37% (7/19) of patients on standard prednisone monotherapy and MMF/lower" exact="prednisone" post="combination, respectively (p = 0.047), highlighting the role of high GC"/>
 <result pre="experienced HBVr. CYC-induced HBVr occurred earlier than that associated with" exact="rituximab" post="(RTX) or tumor necrosis factor inhibitors (TNFi) (8 versus"/>
 <result pre="main driver of HBVr in this cohort was an average" exact="prednisolone" post="daily dose of &amp;gt;5 mg. From these limited data, it"/>
 <result pre="as 53%, but was essentially nullified by the use of" exact="lamivudine" post="or entecavir. 63–65 In the setting of rheumatic diseases,"/>
 <result pre="and case series showing no safety signals for HBVr with" exact="secukinumab" post="(a human IgG1k anti-IL17A monoclonal antibody)89–92 or ixekizumab (a"/>
 <result pre="(a humanized monoclonal anti-IL17A antibody).93,94 The risk for HBVr with" exact="secukinumab" post="was studied in a multicenter prospective cohort study of"/>
 <result pre="these data, it appears that the risk for HBVr with" exact="ustekinumab" post="is similar to that of TNF inhibitors and the"/>
 <result pre="with another currently under investigation (filgotinib). As for psoriatic arthritis," exact="tofacitinib" post="is the only JAK inhibitor currently approved for use"/>
 <result pre="is the only JAK inhibitor currently approved for use after" exact="methotrexate" post="or other csDMARD failure. Data for their HBVr potential"/>
 <result pre="the HBsAg positive patients were prophylactically treated with antivirals upon" exact="tofacitinib" post="initiation and did not experience HBVr. Amongst the four"/>
 <result pre="antivirals, two had HBVr after 6 and 12 months of" exact="tofacitinib" post="therapy, with one having only virological and the other"/>
 <result pre="were being cotreated with low-dose corticosteroids (5 and 10 mg of" exact="prednisolone" post="daily, respectively). Patients who were HBsAg negative/anti-HBc positive did"/>
 <result pre="of drug-related hepatotoxicity should be also of concern (especially for" exact="methotrexate" post="and leflunomide) and, thus, screening should be performed in"/>
 <result pre="antigen; HBV-DNA, HBV-deoxyribonucleic acid; HBVr, hepatitis B virus reactivation; TAF," exact="tenofovir" post="alafenamide; TDF, tenofovir disoproxil fumarate. Table 4. Risk of"/>
 <result pre="acid; HBVr, hepatitis B virus reactivation; TAF, tenofovir alafenamide; TDF," exact="tenofovir" post="disoproxil fumarate. Table 4. Risk of HBVr stratified per"/>
 <result pre="analogues (NAs) with high barrier to genetic resistance, such as" exact="entecavir" post="(ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF)"/>
 <result pre="with high barrier to genetic resistance, such as entecavir (ETV)," exact="tenofovir" post="disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are the"/>
 <result pre="resistance, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and" exact="tenofovir" post="alafenamide (TAF) are the antiviral agents of choice (Figure"/>
 <result pre="al.A randomized, controlled trial of interferon alfa-2b alone and after" exact="prednisone" post="withdrawal for the treatment of chronic hepatitis B. The"/>
 <result pre="et al.Prednisolone priming enhances Th1 response and efficacy of subsequent" exact="lamivudine" post="therapy in patients with chronic hepatitis B. Hepatology2000; 32:"/>
 <result pre="B. Hepatology2000; 32: 604–609.10960456 22HoofnagleJHDavisGLPappasSC, et al.A short course of" exact="prednisolone" post="in chronic type B hepatitis. Report of a randomized,"/>
 <result pre="the tip of the iceberg?Hepatology2015; 61: 703–711.25412906 34LaohapandCArromdeeETanwandeeTLong-term use of" exact="methotrexate" post="does not result in hepatitis B reactivation in rheumatologic"/>
 <result pre="in vitro. J Viral Hepat1999; 6: 229–236.10607235 39YingCDe ClercqENeytsJRibavirin and" exact="mycophenolic acid" post="potentiate the activity of guanine- and diaminopurine-based nucleoside analogues"/>
 <result pre="suppressing hepatitis B virus replication in liver recipients who developed" exact="lamivudine" post="resistance-no beneficial effect. Transplantation2001; 71: 154–156.11211184 42LiXTianJWuJ, et al.A"/>
 <result pre="Transplantation2001; 71: 154–156.11211184 42LiXTianJWuJ, et al.A comparison of a standard-dose" exact="prednisone" post="regimen and mycophenolate mofetil combined with a lower prednisone"/>
 <result pre="standard-dose prednisone regimen and mycophenolate mofetil combined with a lower" exact="prednisone" post="dose in chinese adults with idiopathic nephrotic syndrome who"/>
 <result pre="Intern Med2016; 164: 30–40.26595058 63HsuCHsiungCASuIJ, et al.A revisit of prophylactic" exact="lamivudine" post="for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a"/>
 <result pre="47: 844–853.18302293 64LauGKKYiuHHYFongDYT, et al.Early is superior to deferred preemptive" exact="lamivudine" post="therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology2003; 125:"/>
 <result pre="patients undergoing chemotherapy. Gastroenterology2003; 125: 1742–1749.14724827 65HuangHLiXZhuJ, et al.Entecavir vs" exact="lamivudine" post="for prevention of hepatitis B virus reactivation among patients"/>
 <result pre="66PyrpasopoulouADoumaSVassiliadisT, et al.Reactivation of chronic hepatitis B virus infection following" exact="rituximab" post="administration for rheumatoid arthritis. Rheumatol Int2011; 31: 403–404.19830433 67HuiC-KCheungWWWZhangH-Y,"/>
 <result pre="Ann Hematol2011; 90: 1219–1223.21520001 71HuangY-HHsiaoL-THongY-C, et al.Randomized controlled trial of" exact="entecavir" post="prophylaxis for rituximab-associated hepatitis B virus reactivation in patients"/>
 <result pre="J Clin Oncol2013; 31: 2765–2772.23775967 72MitroulisIHatzaraCKandiliA, et al.Long-term safety of" exact="rituximab" post="in patients with rheumatic diseases and chronic or resolved"/>
 <result pre="risk of hepatitis B virus reactivation in HBsAg-negative/anti-HBc-positive carriers receiving" exact="rituximab" post="for rheumatoid arthritis: a retrospective multicenter italian study. J"/>
 <result pre="characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving" exact="rituximab" post="for rheumatoid arthritis. Clin Exp Rheumatol35: 831–836.28375829 77KimPSHoGYPretePE, et"/>
 <result pre="Clin Exp Rheumatol35: 831–836.28375829 77KimPSHoGYPretePE, et al.Safety and efficacy of" exact="abatacept" post="in eight rheumatoid arthritis patients with chronic hepatitis B."/>
 <result pre="B. Arthritis Care Res2012; 64: 1265–1268. 78PadovanMFilippiniMTincaniA, et al.Safety of" exact="abatacept" post="in rheumatoid arthritis with serologic evidence of past or"/>
 <result pre="68: 738–743. 79FanouriakisAVassilopoulosDRepaA, et al.Hepatitis B reactivation following treatment with" exact="abatacept" post="in a patient with past hepatitis B virus infection."/>
 <result pre="agents targeting interleukins, immunoglobuli. Clin Microbiol Infect2018; 24: S21–S40.29447987 83NagashimaTMinotaSLong-term" exact="tocilizumab" post="therapy in a patient with rheumatoid arthritis and chronic"/>
 <result pre="1838–1840. 84TsuboiHTsujiiANampeiA, et al.A patient with rheumatoid arthritis treated with" exact="tocilizumab" post="together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis"/>
 <result pre="al.A patient with rheumatoid arthritis treated with tocilizumab together with" exact="lamivudine" post="prophylaxis after remission of infliximab-reactivated hepatitis B. Mod Rheumatol2011;"/>
 <result pre="infliximab-reactivated hepatitis B. Mod Rheumatol2011; 21: 701–705.21626075 85KishidaDOkudaYOnishiM, et al.Successful" exact="tocilizumab" post="treatment in a patient with adult-onset Still’s disease complicated"/>
 <result pre="amyloid A amyloidosis. Mod Rheumatol2011; 21: 215–218.20931272 86ChenL-FMoY-QJingJ, et al.Short-course" exact="tocilizumab" post="increases risk of hepatitis B virus reactivation in patients"/>
 <result pre="Int J Rheum Dis2017; 20: 859–869.28160426 87AhnSSJungSMSongJJ, et al.Safety of" exact="tocilizumab" post="in rheumatoid arthritis patients with resolved hepatitis B virus"/>
 <result pre="vulgaris in a hepatitis B virus carrier successfully treated with" exact="secukinumab" post="and entecavir combination therapy. Eur J Dermatol2017; 27: 185–186.27965188"/>
 <result pre="a hepatitis B virus carrier successfully treated with secukinumab and" exact="entecavir" post="combination therapy. Eur J Dermatol2017; 27: 185–186.27965188 91FeasterBClineAFeldmanSRSecukinumab for"/>
 <result pre="JAAD Case Reports2019; 5: 150–152.30733983 95ChiuHHuiRHuangY, et al.Safety Profile of" exact="secukinumab" post="in treatment of patients with psoriasis and concurrent hepatitis"/>
 <result pre="Derm Venereol2018; 98: 829–834.29972221 96ChiuH-YChenC-HWuM-S, et al.The safety profile of" exact="ustekinumab" post="in the treatment of patients with psoriasis and concurrent"/>
</results>
